Celebrating 20 Years of Training in Botox®, Aesthetic Medicine
and Medical Weight Management

Days
Hours
Minutes

Save 25% on Hands-on Botox® Training

All 2026 dates on sale. Register before December 31!

Celebrating 20 Years of Excellence in Botox®, Aesthetic Medicine & Medical Weight Management Training & Certification

Temple Hollowing on GLP‑1s: New Restylane Contour FDA Approval

For many patients on GLP‑1 medications, temple hollowing has become one of the most visible—and distressing—signs of rapid, medication‑assisted weight loss. The combination of upper‑face deflation, deeper shadows, and a subtly skeletal look can clash with how healthy and energized these patients feel after losing weight.
Essential Anatomy for Botox® Injection Sites

Against that backdrop, Restylane Contour has received U.S. FDA approval for the correction of temple hollowing in adults 21 and older, providing an on‑label hyaluronic acid (HA) filler option for one of the key regions involved in “Ozempic face.” This new indication extends Restylane Contour’s use beyond cheek and midface augmentation and formally recognizes the temporal region as a distinct target for nonsurgical rejuvenation.

In its clinical study, treatment with Restylane Contour led to clinically meaningful improvement in temple volume and contour, with high patient and investigator satisfaction and durable results in many subjects out to roughly 18 months. Adverse events were generally mild to moderate and consistent with the expected safety profile of HA fillers in other facial areas, with no new safety signal identified specific to the temples.

For injectors, the approval is less about introducing temple treatment—which experienced clinicians have already been doing off‑label—and more about codifying a structured approach to a high‑impact, anatomically complex region in a rapidly growing patient population: individuals on GLP‑1s whose faces are changing faster than their chronological age would suggest.

In this article, you’ll discover: 

  • Explain how GLP‑1–driven weight loss contributes to temple hollowing and the “Ozempic face” phenotype in your aesthetic patients. 
  • Understand where Restylane Contour’s new FDA approval for temple hollowing fits within pan‑facial treatment planning for GLP‑1 patients. 
  • Structure a focused GLP‑1‑aware intake and facial assessment that considers temples, midface, and lower face together. 
  • Design conservative, staged temple filler plans that anticipate possible GLP‑1 dose changes and weight regain, reducing overcorrection risk. 
  • Communicate effectively with GLP‑1 patients about expected facial changes, timing of fillers, and the role of hyaluronidase if adjustments are needed later.

Table of Contents

Why GLP‑1 Therapy Drives Temple Hollowing and “Ozempic Face”

As GLP‑1 receptor agonists move into mainstream use, more patients are losing 10–30% of their body weight under medical supervision—and their faces are often the first place that change shows up. The “Ozempic face” pattern consistently includes hollowing of the temples, infraorbital region, and submalar areas, with earlier onset of laxity in the lower face and neck.

GLP‑1 RAs reduce appetite, slow gastric emptying, and improve glycemic control, driving reductions in caloric intake and total fat mass. Facial fat pads—especially in midface and temporal compartments—appear particularly sensitive; as they deflate, bony landmarks and pre‑existing laxity become more visible, creating the hollowed appearance patients notice.

The temporal region is a prime example. Loss of temporal fat produces concavity near the hairline, deeper lateral shadows, and loss of upper‑face support, which patients interpret as “I look older and more tired” even with improved metabolic health.

From News to Practice: Working Up GLP‑1 Patients With Temple Hollowing

The key question isn’t just whether you can use Restylane Contour in the temples, but how to evaluate a GLP‑1 patient and stage treatment safely. That starts with making GLP‑1 status a routine part of your intake.

Make GLP‑1 part of standard intake

For any patient presenting with temple hollowing or broader “Ozempic face” concerns, ask about:
  • GLP‑1 agent, dose, duration, and titration pace 
  • Amount of weight lost and whether weight is still changing 
  • Typical intake pattern (especially protein), tendency to “forget to eat” or graze, and any obvious nutrition red flags such as marked fatigue or hair changes

This gives you a sense of how aggressively their soft tissues have been stressed and whether to recommend basic nutrition support before or alongside aesthetic intervention.

Examine the whole face, not just the temples

Temple hollowing in GLP‑1 patients rarely exists in isolation. On exam, look at:
  • Upper face: degree of temporal concavity, lateral brow support, periorbital hollowing, and lateral shadow patterns 
  • Midface: malar flattening, infraorbital volume loss, lid–cheek junction 
  • Lower face and neck: jowling, pre‑jowl sulcus, labiomental hollowing, platysmal bands, early neck laxity
Capture high‑quality baseline photos at the current weight, and if possible, at later milestones. That visual record supports expectation setting and later decisions about staging and overcorrection.

When to treat the temples first

Restylane Contour’s temple indication offers a powerful option, but it should be deployed in sequence, not in isolation:
  • Lead with temples when concavity, strong lateral shadowing, and skeletal upper‑face appearance dominate the concern. 
  • Lead with midface when cheek deflation and tear troughs are primary; in some patients, restoring midface support alone softens temple hollowing. 
  • Combine temples and lower face in stages when jawline collapse and early jowling accompany temporal hollowing.
Documenting why you chose to start where you did supports both clinical clarity and medico‑legal protection.

Staged, conservative dosing

Because GLP‑1 trajectories are dynamic, “full correction in one sitting” is rarely ideal:
  • Start with modest volumes per temple and reassess after product integration, especially if weight is still declining. 
  • Schedule planned follow‑ups—at 4–6 weeks, then at 3–6 months—to layer volume only as needed. 
  • Tie reviews not only to time but also to weight milestones (for example, 10–15% total weight loss or several months after a dose change).
This staged approach keeps patients looking supported during active weight loss and reduces the risk of them looking overfilled if their weight later increases.

Overcorrection and Weight Regain: Setting Expectations

Many GLP‑1 patients will move through at least three phases—active loss, time at their lowest weight, and some degree of weight regain—and each can change how previous filler looks. Overcorrection becomes a predictable risk if you chase full normalization at the nadir weight.

Rapid, GLP‑1–driven fat loss shrinks facial compartments; injectors understandably rebuild volume in temples, midface, and jawline. Yet observational data show that a substantial proportion of patients regain a significant share of lost weight after GLP‑1 dose reduction or cessation, especially when behavioral and nutritional support are limited. As fat returns, previously “just right” volumes can look excessive, with overly convex temples or heavy midface, particularly if large volumes were placed quickly at the lowest weight.

Short counseling script

You can fold this into your standard conversation:
  • “Your face today reflects where you are in your weight‑loss journey. If your medication or weight changes, your face can change again.” 
  • “We’ll treat areas like your temples gradually so you look better now, but also reduce the chance of looking overfilled if you regain some weight.” 
  • “If we ever feel an area looks too full after weight changes, we can adjust—sometimes using hyaluronidase to gently reduce HA filler.”
Document that you discussed the dynamic nature of weight, the rationale for conservative staging, and the possibility of future hyaluronidase use.

Practical ways to reduce overcorrection risk

  • Stage larger corrections over multiple visits instead of trying to fix everything at once. 
  • Emphasize deep, structural support more than aggressive superficial effacement. 
  • Maintain a clear, documented hyaluronidase protocol aligned with current guidance so both you and the patient know how you will handle an overfilled result if it occurs.

A Brief Note on Nutrition (and When to Link Out)

Aesthetics in GLP‑1 patients don’t exist in isolation from nutrition and body composition. Reduced appetite and intake can lead to lower protein and micronutrient consumption and increased lean‑mass loss, particularly without resistance training, which may contribute to a frailer facial appearance in some patients. A quick screen for severe fatigue, hair thinning, very low intake, or suspected deficiencies can help you identify patients who may benefit from nutritional support before extensive aesthetic work.

For step‑by‑step nutrition strategies and sample meal frameworks, you can direct readers to a companion article on guided nutrition plans for GLP‑1 patients, instead of expanding this section here.

Key Takeaways

  • Injectables are your foundation. Botox® and dermal fillers have the highest demand, lowest barrier to entry, and fastest path to revenue. Start here.
  • The three core services work together. Injectables create recurring revenue, lasers deliver premium pricing, and facial rejuvenation maintains patient engagement between major treatments.
  • Don’t offer everything at once. Master core services first, then expand strategically based on patient demand and practice goals.
  • Revenue potential is significant. Injectables alone can generate $75K-$150K annually. Add lasers and facial rejuvenation to reach $200K-$400K+ in aesthetic revenue.
  • Patient journeys maximize value. Create treatment plans that incorporate multiple services over time to increase lifetime patient value and deliver better outcomes.
  • Strategic expansion matters. Start with injectables (0-3 months), add facial rejuvenation (3-6 months), then invest in lasers (12-18 months) as your patient base grows.

Clinician FAQ: GLP‑1 Patients and Temple Filler

Do I need to stop GLP‑1s before doing fillers or neurotoxin? 

For nonsurgical aesthetic treatments like HA fillers and neuromodulators, current evidence and expert experience do not identify a specific requirement to stop GLP‑1 therapy. Decisions to hold a GLP‑1 are generally tied to anesthesia and surgery or significant GI symptoms, not to routine injectable visits. 

When should I start talking about fillers with GLP‑1 patients? 

You can introduce the concept early—at or near GLP‑1 initiation or at the first aesthetic consult—without recommending immediate treatment. A simple forecast such as, “You may notice hollowing in your temples or cheeks as you lose weight; if that bothers you, there are nonsurgical options we can discuss later,” normalizes the change and plants the seed without pressure. 

How do I phrase the ‘if this happens, we can help’ conversation? 

Consider: “GLP‑1 medications often change the way the face looks before anywhere else—sometimes that means more hollow temples or looser skin around the jawline. That’s not a sign of damage, but if you don’t like those changes, we have nonsurgical tools, including HA fillers for temple hollowing and cheek support, and devices that can help tighten skin on the face and body. We don’t have to do anything today; I just want you to know what to expect and what options exist.” 

Do GLP‑1 medications make filler dissolve faster or last less long? 

There is currently no evidence that GLP‑1 medications directly change the longevity of HA fillers or neuromodulators. What changes is the underlying fat and soft‑tissue volume, so as patients lose or regain weight, their facial contours shift, making filler appear less noticeable or more prominent even though the product itself is behaving normally. 

Should I wait until a GLP‑1 patient’s weight is stable before treating temple hollowing? 

You don’t have to wait for complete weight stability, but you should adapt your strategy to where they are in the curve. During active weight loss, use conservative, staged volumes and emphasize that adjustments may be needed as they lose more weight; once weight has plateaued for several months, fuller correction becomes more reasonable, though the possibility of future weight changes remains. 

What red flags should make me defer or modify aesthetic treatment? 

Consider pausing or simplifying treatment plans if the patient reports severe or ongoing GI side effects, very low caloric intake, clear signs of undernutrition, very rapid ongoing loss, or poorly controlled comorbidities. In those cases, focus on minimal, low‑risk interventions and coordinate with the prescribing clinician or a dietitian before committing to larger, multi‑session aesthetic plans.

Ready to Get Trained for the GLP‑1 Era?

Temple hollowing, “Ozempic face,” and GLP‑1‑related skin changes are now everyday realities in aesthetic practice. If you want to feel confident managing both the metabolic and aesthetic sides of these patients, you need training that covers the full picture.

IAPAM offers integrated training in:

  • CME‑Accredited GLP‑1 Certification for Medical Weight Loss – Understand evidence‑based GLP‑1 protocols, counseling, and long‑term weight‑maintenance strategies so you can manage these medications safely and confidently. 
  • Introduction to Cosmetic Injectables – Master Botox® and dermal fillers with a focus on full‑face assessment, anatomy, and safe, staged correction for areas like the temples, cheeks, and jawline. 
  • Lasers, Skin & Body Contouring – Learn laser safety, non‑surgical skin tightening, and body contouring options you can use to address loose skin and contour changes as patients lose weight.

Our training bundles are designed around how successful practices actually grow—pairing medical weight loss and GLP‑1 expertise with core aesthetic skills so you can support patients through every stage of their transformation.

View our current aesthetic and GLP‑1 training options →

About IAPAM: The International Association for Physicians in Aesthetic Medicine has been training physicians, nurse practitioners, and physician assistants in aesthetic medicine for over 20 years. Our courses are AMA PRA Category 1 CME accredited and taught by board-certified dermatologists and industry experts.

Hands-On BOTOX® Training in Scottsdale, Arizona
Gain the Confidence to Start Seeing Patients Right Away!

Attend the most comprehensive accredited AMA PRA CAT 1 CME Botox® training weekend, learn how to create a profitable practice with the top 5 most lucrative non-invasive treatments.

Add-on GLP-1 agonists for weight loss and/or business for 4-days of comprehensive, fun CME-accredited training like none other! 

Hands-on Botox® Training for Physicians

Hands-on Botox® injection training is done in a clean multi-million dollar medspa, NOT in a hotel. We provide live models and product, you show up and enjoy the weekend with our expert instructors!

April 10-13
Only 2 spots left!

Scottsdale, Arizona 

Save $3,605 when you become an IAPAM member and register to attend all 4-days!

References:

  1. Galderma – Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing – March 22, 2026
  2. U.S. Food and Drug Administration (FDA) – Restylane® Contour – P140029/S032 – July 12, 2021
  3. Facial Cosmetic Surgery Clinic – Ozempic Face: Facial Changes After GLP-1 Weight Loss and How to Correct Them – December 7, 2025
  4. Journal of Cosmetic Dermatology / Wiley – The Role of GLP‑1 Agonists in Esthetic Medicine: Exploring the Intersection of Metabolic and Aesthetic Care – December 7, 2024
  5. Aesthetic Surgery Journal Open Forum (PMC) – Nonsurgical Aesthetic Treatment of the Face and Neck in GLP‑1 Patients – January 20, 2026
  6. National Library of Medicine / StatPearls (example GLP‑1 mechanism reference) – Mechanisms of Glucagon‑Like Peptide‑1 Receptor Agonist Weight-Loss Effects – November 27, 2025
  7. Nutrition.org (American Society for Nutrition) – Nutritional Priorities to Support GLP‑1 Therapy for Obesity – May 29, 2025
  8. Newswise – Nutritional Priorities to Support GLP‑1 Therapy for Obesity – May 26, 2025
  9. JCAD (Journal of Clinical and Aesthetic Dermatology) – Guideline for the Safe Use of Hyaluronidase in Aesthetic Practice – January 19, 2017
  10. Cosmedic Training / JCAD PDF (duplicate guidance, backup) – The Use of Hyaluronidase in Aesthetic Practice – 2017
  11. University of Oxford – New study finds that stopping weight‑loss drugs is linked to faster regain than ending a diet – January 8, 2026
  12. Ophthalmology Advisor – Weight Regain Seen After Cessation of GLP‑1 Receptor Agonists in Adults With Overweight or Obesity – March 5, 2026
  13. IAPAM – CME Accredited GLP‑1 Certification for Medical Weight Loss – January 5, 2026
  14. IAPAM – Juvéderm® Dermal Fillers: A Guide for Certified Aesthetic Providers – November 4, 2024
  15. IAPAM – Choosing a Dermal Filler (Hyaluronic Acid) – June 24, 2024
  16. IAPAM – Non‑Surgical Chin Augmentation: Restylane® Lyft FDA Approval – November 30, 2025
  17. Dr. Olivia Hutchinson – The Effects of Rapid Weight Loss from GLP‑1s: Understanding the Impact on the Face – February 27, 2026

Contains: Emerging trends, expert discussions, recommendations, technique comparisons… and more!